The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the fundamental principle U that uh that there's this cohort of of Androgen responsive genes um is pretty consistent and if you look at them in at any of these different stages in the a b a benign cell signature a localized prostate cancer signature Androgen responsive sign or even an advanced disease the same theme is true that is the tumors that rely and have less of a a signature that is less um AR high like they are more aggressive
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
cancers that are more aggressive are probably less reliant on the traditional growth and differentiation factors that a prostate epithelial cell has in its normal micro environment
these tumors rely on different growth mechanisms to be to be aggressive and they have different vulnerabilities in terms of sensitivity to agents that we may use when they presented at later stages